Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 third quarter ended June 30, 2025. The Company is hosting a conference call today, August 7, 2025, ...

Over 60% of patients who received ervogastat plus clesacostat for 48 weeks achieved MASH resolution without fibrosis ...

Sanofi secures exclusive rights to develop plozasiran in Greater China, enhancing treatment options for hypertriglyceridemia ...

Arrowhead Pharmaceuticals’ subsidiary Visirna Therapeutics has entered an asset purchase agreement with Sanofi for the rights ...

The deal with Arrowhead's Visirna Therapeutics subsidiary – which also includes $265 million in milestones tied to potential ...

US RNA interference (RNAi)specialist Arrowhead Pharmaceuticals (Nasdaq: ARWR) today announced that its majority-owned subsidiary Visirna Therapeutics has signed an asset purchase agreement with France ...

Sanofi will acquire rights to develop and commercialize the drug for $130 million upfront, with Visirna eligible for up to $265 million in milestone payments.

Arrowhead Pharmaceuticals strikes a $130M+ deal with Sanofi for plozasiran in Greater China, targeting high triglyceride ...

Sanofi is handing over $130 million upfront for the China rights to Arrowhead Pharmaceuticals’ rare metabolic disease ...

The majority of liver cancer cases could be prevented by reducing levels of viral hepatitis, alcohol consumption and MASLD (metabolic dysfunction-associated steatotic liver disease – previously called ...

In a new paper, a team from Yale and Fred Hutch has found autoantibody reactivity could predict cancer patients' response to immune checkpoint inhibitors.

Full B Cell Depletion Achieved in Blood, Spleen, and Lymph Nodes in Non-Human Primate Study Data Supports the Nomination of OTX-201, a Novel In Vivo CAR-T Therapy, as Orbital’s First Product Candidate ...